NL-OMON49795
Recruiting
Phase 3
Convalescent Plasma Therapy from Recovered Patients to Treat COVID-19 Early in SARS-CoV-2 Disease - CoV-Early
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Erasmus MC, Universitair Medisch Centrum Rotterdam
- Enrollment
- 690
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •PCR\-confirmed COVID\-19
- •Symptomatic (e.g but not limited to fatigue, fever, cough, dyspnoe, loss of
- •taste or smell, diarrhea, falls or confusion)
- •70 years or older OR 50\-69 years and 1 or more of the risk factors described
- •1\. A/ Medical history
- •Obesity with BMI 35 or higher
- •Born as a male person
- •History of cardiac or pulmonary disease (e.g. but not limited to atrial
- •fibrillation, coronary artery disease, heart failure, COPD, asthma)
- •History of neurological disease (e.g. a history of stroke or any other
Exclusion Criteria
- •Life expectancy \<28 days in the opinion of the treating physician
- •Patient or legal representative is unable to provide written informed consent
- •Symptomatic for 8 days or more
- •Being admitted to the hospital at the informed consent procedure
- •Known previous history of transfusion\-related acute lung injury
- •Known IgA deficiency
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
Effect of convalescent plasma in COVID-19 patientsHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereCTRI/2020/06/025803Institute of Liver and Biliary Sciences400
Active, not recruiting
Phase 2
se of plasma of cured person to treat patient with severe covid-19Coronavirus infection, transfusion, C23, A00-B99, Coronavirus OC43, Human.A00-B99RBR-7f4mt9fHemocentro de Ribeirão Preto
Completed
Phase 2
Effect of convalescent plasma in COVID-19 patientsHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereCTRI/2020/04/024706Institute of Liver and Biliary Sciences29
Recruiting
Not Applicable
Plasma therapy in patient with COVID-19IRCT20200416047099N1Shahid Beheshti University of Medical Sciences10
Completed
Phase 2
Efficacy of Combined Convalescent Plasma Therapy with Oral RNA-dependent RNA Polymerase Inhibitor versus Monoclonal Neutralizing Antibody Therapy among Mild to Moderate COVID-19 in Outpatients: Multicenter, Non-inferiority, Open-label Randomized Controlled TrialMild to moderate COVID-19 (non-severe COVID-19)COVID-19, SARS-CoV-2, favipiravir, sotrovimab, convalescent plasma therapy, monoclonal neutralizing antibodyTCTR20220319002Chulabhorn Royal Academy136